19.56
Oculis Holding Ag stock is traded at $19.56, with a volume of 34,216.
It is up +2.14% in the last 24 hours and up +5.33% over the past month.
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$19.15
Open:
$19.34
24h Volume:
34,216
Relative Volume:
0.92
Market Cap:
$938.88M
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-9.8011
EPS:
-1.9957
Net Cash Flow:
$-57.45M
1W Performance:
+0.31%
1M Performance:
+5.33%
6M Performance:
+25.79%
1Y Performance:
+63.68%
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
OCS
Oculis Holding Ag
|
19.56 | 1.02B | 0 | -75.28M | -57.45M | -1.9957 |
![]()
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
Oct-05-23 | Initiated | Stifel | Buy |
Jun-14-23 | Initiated | BofA Securities | Buy |
Jun-12-23 | Initiated | H.C. Wainwright | Buy |
Jun-08-23 | Initiated | Robert W. Baird | Outperform |
May-10-23 | Initiated | Pareto | Buy |
Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
Oculis Holding AG Announces 2025 AGM Results and Strategic Approvals - TipRanks
Leerink Partners raises Oculis stock price target to $50 from $22 - Investing.com
Oculis Holding AG Reports Outcomes of 2025 Annual General Meeting and Shareholder Approvals - Nasdaq
Oculis Publishes Results of 2025 Annual General Meeting - The Manila Times
REG-Oculis Publishes Results of 2025 Annual General Meeting - TradingView
Citadel Advisors LLC Buys Shares of 22,911 Oculis Holding AG (NASDAQ:OCS) - Defense World
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire Inc.
Oculis to Participate in Upcoming June Investor Conferences - InvisionMag.com
Oculis Holding AG Announces Participation in Upcoming Investor Conferences in June 2025 - Nasdaq
Trend Tracker for (OCS) - news.stocktradersdaily.com
Trend Tracker for (OCSAW) - news.stocktradersdaily.com
HC Wainwright Estimates Oculis’ Q2 Earnings (NASDAQ:OCS) - Defense World
HC Wainwright Weighs in on Oculis’ Q1 Earnings (NASDAQ:OCS) - Defense World
Oculis (NASDAQ:OCS) Sees Large Volume Increase on Analyst Upgrade - Defense World
Oculis (NASDAQ:OCS) Price Target Raised to $33.00 - Defense World
Oculis Publishes Invitation to the Annual General Meeting - The Manila Times
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates - MSN
Oculis Announces 2025 Annual General Meeting Details - TipRanks
Dave To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Oculis Reports Q1 2025 Financial Results and Provides Company Update - The Manila Times
Oculis Holding AG Reports Strong Q1 Progress - TipRanks
Learn to Evaluate (OCSAW) using the Charts - news.stocktradersdaily.com
Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline - MSN
Oculis Holding AG reports results for the quarter ended March 31Earnings Summary - TradingView
Oculis Holding AG Reports Q1 2025 Financial Results - TipRanks
Oculis to Present at Upcoming May Investor Conferences - EIN News
REG-Oculis to Present at Upcoming May Investor Conferences - TradingView
Long Term Trading Analysis for (OCS) - news.stocktradersdaily.com
Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – Still a Buy? - Defense World
Oculis Holding AG (NASDAQ:OCS) Shares Bought by Geode Capital Management LLC - Defense World
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences - The Manila Times
Oculis Holding AG to Present Innovative Late-Stage Pipeline at Major Ophthalmology Conferences in 2025 - Nasdaq
Oculis Holding AG to Present Innovative Late-Stage Pipeline at Major Ophthalmology Conferences in May 2025 - Nasdaq
Oculis Updates Share Capital - The Manila Times
Long Term Trading Analysis for (OCSAW) - news.stocktradersdaily.com
(OCS) Trading Advice - news.stocktradersdaily.com
Chardan Capital Reaffirms Buy Rating for Oculis (NASDAQ:OCS) - Defense World
HC Wainwright Increases Oculis (NASDAQ:OCS) Price Target to $32.00 - Defense World
Oculis (NASDAQ:OCS) Shares Gap Up Following Analyst Upgrade - Defense World
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award - The Manila Times
Stifel maintains Buy rating, $35 target on Oculis shares By Investing.com - Investing.com South Africa
Stifel maintains Buy rating, $35 target on Oculis shares - Investing.com
Oculis Holding AG Unveils Key Clinical Updates and Future Outlook at R&D Day - TipRanks
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets - The Manila Times
Oculis completes enrolment in trials for diabetic macular oedema eye drops - Yahoo
Oculis completes enrollment for pivotal DME treatment trials By Investing.com - Investing.com South Africa
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):